AIDS-Related Cancer in the Era of Highly Active Antiretroviral Therapy (HAART): A Model of the Interplay of the Immune System, Virus, and Cancer.—“On the Offensive—The Trojan Horse is Being Destroyed”— Part A: Kaposi's Sarcoma

References

• Hymes K. B., Cheung T., Greene J. B., Prose N. S., Marcus A., Ballard H., William D. C., Laubenstein L. J. Kaposi's sarcoma in homosexual men—a report of eight cases. Lancet 1981; 2: 598–600, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Siegal F. P., Lopez C., Hammer G. S., Brown A. E., Kornfeld S. J., Gold J., Hassett J., Hirschman S. Z., Cunningham-Rundles C., Adelsberg B. R. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N. Engl. J. Med. 1981; 305: 1439–1444, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Barre-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868–871
   PubMed Web of Science ®Google Scholar
• Penn I. Neoplasia: an example of plasticity of the immune response. Transplant. Proc. 1996; 28: 2089–2093, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Myers B. D., Kessler E., Levi J., Pick A., Rosenfeld J. B., Tikvah P. Kaposi sarcoma in kidney transplant recipients. Arch. Intern. Med. 1974; 133: 307–311, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Beckstead J. H., Wood G. S., Fletcher V. Evidence for the origin of Kaposi's sarcoma from lymphatic endothelium. Am. J. Pathol. 1985; 119: 294–300, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Salahuddin S. Z., Nakamura S., Biberfeld P., Kaplan M. H., Markham P. D., Larsson L., Gallo R. C. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 1988; 242: 430–433, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Weich H. A., Salahuddin S. Z., Gill P., Nakamura S., Gallo R. C., Folkmann J. AIDS-associated Kaposi's sarcoma-derived cells in long-term culture express and synthesize smooth muscle alpha-actin. Am. J. Pathol. 1991; 139: 1251–1258, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chang Y., Cesarman E., Pessin M. S., Lee F., Culpepper J., Knowles D. M., Moore P. S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865–1869, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cesarman E., Chang Y., Moore P. S., Said J. W., Knowles D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 1995; 332: 1186–1191, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dupin N., Grandadam M., Calvez V., Gorin I., Aubin J. T., Havard S., Lamy F., Leibowitch M., Huraux J. M., Escande J. P. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet 1995; 345: 761–762, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schalling M., Ekman M., Kaaya E. E., Linde A., Biberfeld P. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. Nat. Med. 1995; 1: 707–708, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chang Y., Ziegler J., Wabinga H., Katangole-Mbidde E., Boshoff C., Schulz T., Whitby D., Maddalena D., Jaffe H. W., Weiss R. A., Moore P. S. Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma in Africa. Uganda Kaposi's sarcoma study group. Arch. Intern.Med. 1996; 156: 202–204, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Huang Y. Q., Li J. J., Kaplan M. H., Poiesz B., Katabira E., Zhang W. C., Feiner D., Friedman-Kien A. E. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet 1995; 345: 759–761, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rady P. L., Yen A., III, Martin R. W., Nedelcu I., Hughes T. K., Tyring S. K. Herpesvirus-like DNA sequences in classic Kaposi's sarcomas. J. Med. Virol. 1995; 47: 179–183, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Collandre H., Ferris S., Grau O., Montagnier L., Blanchard A. Kaposi's sarcoma and new herpesvirus. Lancet 1995; 345: 1043, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Whitby D., Howard M. R., Tenant-Flowers M., Brink N. S., Copas A., Boshoff C., Hatzioannou T., Suggett F. E., Aldam D. M., Denton A. S. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995; 346: 799–802, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Moore P. S., Kingsley L. A., Holmberg S. D., Spira T., Gupta P., Hoover D. R., Parry J. P., Conley L. J., Jaffe H. W., Chang Y. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 1996; 10: 175–180, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jenner R. G., Boshoff C. The molecular pathology of Kaposi's sarcoma-associated herpesvirus. Biochim. Biophys. Acta 2002; 1602: 1–22, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sarid R., Sato T., Bohenzky R. A., Russo J. J., Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat. Med. 1997; 3: 293–298, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Osman M., Kubo T., Gill J., Neipel F., Becker M., Smith G., Weiss R., Gazzard B., Boshoff C., Gotch F. Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J. Virol. 1999; 73: 6136–6140, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brander C., Suscovich T., Lee Y., Nguyen P. T., O'Connor P., Seebach J., Jones N. G., van Gorder M., Walker B. D., Scadden D. T. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus. J. Immunol. 2000; 165: 2077–2083, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ensoli B., Nakamura S., Salahuddin S. Z., Biberfeld P., Larsson L., Beaver B., Wong-Staal F., Gallo R. C. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989; 243: 223–226, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Coscoy L., Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 8051–8056, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Miles S. A., Rezai A. R., Salazar-Gonzalez J. F., Vander, Meyden M., Stevens R. H., Logan D. M., Mitsuyasu R. T., Taga T., Hirano T., Kishimoto T. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 4068–4072, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Samaniego F., Markham P. D., Gendelman R., Watanabe Y., Kao V., Kowalski K., Sonnabend J. A., Pintus A., Gallo R. C., Ensoli B. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am. J. Pathol. 1998; 152: 1433–1443, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Meade-Tollin L. C., Way D., Witte M. H. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem. 1999; 101: 305–316
   PubMed Web of Science ®Google Scholar
• Barillari G., Sgadari C., Palladino C., Gendelman R., Caputo A., Morris C. B., Nair B. C., Markham P., Nel A., Sturzl M., Ensoli B. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J. Immunol. 1999; 163: 1929–1935, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vogel J., Hinrichs S. H., Reynolds R. K., Luciw P. A., Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335: 606–611, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Prakash O., Tang Z. Y., He Y. E., Ali M. S., Coleman R., Gill J., Farr G., Samaniego F. Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 tat-expressing transgenic mice. J. Natl. Cancer Inst. 2000; 92: 721–728, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fiorelli V., Barillari G., Toschi E., Sgadari C., Monini P., Sturzl M., Ensoli B. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 1999; 162: 1165–1170, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ganju R. K., Munshi N., Nair B. C., Liu Z. Y., Gill P., Groopman J. E. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J. Virol. 1998; 72: 6131–6137, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gill P. S., Tsai Y. C., Rao A. P., Spruck C. H., III, Zheng T., Harrington W. A., Jr., Cheung T., Nathwani B., Jones P. A. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 8257–8261, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dupin N., Fisher C., Kellam P., Ariad S., Tulliez M., Franck N., van Marck E., Salmon D., Gorin I., Escande J. P., Weiss R. A., Alitalo K., Boshoff C. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 4546–4551, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Judde J. G., Lacoste V., Briere J., Kassa-Kelembho E., Clyti E., Couppie P., Buchrieser C., Tulliez M., Morvan J., Gessain A. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J. Natl. Cancer Inst. 2000; 92: 729–736, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Beral V., Peterman T. A., Berkelman R. L., Jaffe H. W. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?. Lancet 1990; 335: 123–128, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cheung T. W., Siegal F. P. Kaposi's Sarcoma in Women with AIDS. Proceedings of the Fifth International Conference on AIDS, StockholmSweden 1989; 5, Abs MBP 297-
   Google Scholar
• Goedert J. J., Cote T. R., Virgo P., Scoppa S. M., Kingma D. W., Gail M. H., Jaffe E. S., Biggar R. J. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351: 1833–1839, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Levine A. M., Tulpule A. Clinical aspects and management of AIDS-related Kaposi's sarcoma. Eur. J. Cancer 2001; 37: 1288–1295, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Meduri G. U., Stover D. E., Lee M., Myskowski P. L., Caravelli J. F., Zaman M. B. Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical, radiographic, and pathologic manifestations. Am. J. Med. 1986; 81: 11–18, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Stahl R. E., Friedman-Kien A., Dubin R., Marmor M., Zolla-Pazner S. Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am. J. Med. 1982; 73: 171–178, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chachoua A., Krigel R., Lafleur F., Ostreicher R., Speer M., Laubenstein L., Wernz J., Rubenstein P., Zang E., Friedman-Kien A. Prognostic factors and staging classification of patients with epidemic Kaposi's sarcoma. J. Clin. Oncol. 1989; 7: 774–780, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Krown S. E., Metroka C., Wernz J. C. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin.Oncol. 1989; 7: 1201–1207, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Bower M., Fox P., Fife K., Gill J., Nelson M., Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105–2111, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Holkova B., Takeshita K., Cheng D. M., Volm M., Wasserheit C., Demopoulos R., Chanan-Khan A. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J. Clin. Oncol. 2001; 19: 3848–3851, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cattelan A. M., Calabro M. L., Aversa S. M., Zanchetta M., Meneghetti F., De Rossi A., Chieco-Bianchi L. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur. J. Cancer 1999; 35: 1809–1815, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pati S., Pelser C. B., Dufraine J., Bryant J. L., Reitz M. S., Jr., Weichold F. F. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002; 99: 3771–3779, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zala C., Ochoa C., Krolewiecki A., Patterson P., Cahn P., Crawford R. I., Montaner J. S. Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals. AIDS 2000; 14: 2217–2218, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chan J., Kravcik S., Angel J. B. Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J. Acquir. Immune Defic. Syndr. 1999; 22: 209–210, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Walmsley S., Northfelt D. W., Melosky B., Conant M., Friedman-Kien A. E., Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J. Acquir. Immune Defic. Syndr. 1999; 22: 235–246, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chak L. Y., Gill P. S., Levine A. M., Meyer P. R., Anselmo J. A., Petrovich Z. Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. J. Clin. Oncol. 1988; 6: 863–867, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Nobler M. P., Leddy M. E., Huh S. H. The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J. Clin. Oncol. 1987; 5: 107–112, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Hartshorn K. L., Neumeyer D., Vogt M. W., Schooley R. T., Hirsch M. S. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res. Hum. Retrovir. 1987; 3: 125–133, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Monini P., Carlini F., Sturzl M., Rimessi P., Superti F., Franco M., Melucci-Vigo G., Cafaro A., Goletti D., Sgadari C., Butto' S., Leone P., Chiozzini C., Barresi C., Tinari A., Bonaccorsi A., Capobianchi M. R., Giuliani M., di Carlo A., Andreoni M., Rezza G., Ensoli B. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. J. Virol. 1999; 73: 4029–4041, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Groopman J. E., Gottlieb M. S., Goodman J., Mitsuyasu R. T., Conant M. A., Prince H., Fahey J. L., Derezin M., Weinstein W. M., Casavante C. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 1984; 100: 671–676, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Krown S. E., Gold J. W., Niedzwiecki D., Bundow D., Flomenberg N., Gansbacher B., Brew B. J. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 1990; 112: 812–821, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Evans L. M., Itri L. M., Campion M., Wyler-Plaut R., Krown S. E., Groopman J. E., Goldsweig H., Volberding P. A., West S. B., Mitsuyasu R. T. Interferon-alpha 2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma. J. Immunother. 1991; 10: 39–50, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• de Wit R., Danner S. A., Bakker P. J., Lange J. M., Eeftinck Schattenkerk J. K., Veenhof C. H. Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma. J. Intern. Med. 1991; 229: 35–40, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Volberding P. A., Abrams D. I., Conant M., Kaslow K., Vranizan K., Ziegler J. Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann. Intern. Med. 1985; 103: 335–338, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kaplan L., Abrams D., Volberding P. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen. Cancer Treat. Rep. 1986; 70: 1121–1122, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Laubenstein L. J., Krigel R. L., Odajnyk C. M., Hymes K. B., Friedman-Kien A., Wernz J. C., Muggia F. M. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J. Clin. Oncol. 1984; 2: 1115–1120, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gelmann E. P., Longo D., Lane H. C., Fauci A. S., Masur H., Wesley M., Preble O. T., Jacob J., Steis R. Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. Am. J. Med. 1987; 82: 456–462, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Bogner J. R., Kronawitter U., Rolinski B., Truebenbach K., Goebel F. D. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. J. Acquir. Immune Defic. Syndr. 1994; 7: 463–468, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 1995; 13: 914–920, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Northfelt D. W., Dezube B. J., Thommes J. A., Miller B. J., Fischl M. A., Friedman-Kien A., Kaplan L. D., Du Mond C., Mamelok R. D., Henry D. H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 1998; 16: 2445–2451, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Saville M. W., Lietzau J., Pluda J. M., Feuerstein I., Odom J., Wilson W. H., Humphrey R. W., Feigal E., Steinberg S. M., Broder S. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995; 346: 26–28, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Welles L., Saville M. W., Lietzau J., Pluda J. M., Wyvill K. M., Feuerstein I., Figg W. D., Lush R., Odom J., Wilson W. H., Fajardo M. T., Humphrey R. W., Feigal E., Tuck D., Steinberg S. M., Broder S., Yarchoan R. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J. Clin. Oncol. 1998; 16: 1112–1121, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sgadari C., Toschi E., Palladino C., Barillari G., Carlei D., Cereseto A., Ciccolella C., Yarchoan R., Monini P., Sturzl M., Ensoli B. Mechanism of paclitaxel activity in Kaposi's sarcoma. J. Immunol. 2000; 165: 509–517, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dezube B. J., Von Roenn J. H., Holden-Wiltse J., Cheung T. W., Remick S. C., Cooley T. P., Moore J., Sommadossi J. P., Shriver S. L., Suckow C. W., Gill P. S. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS clinical trial group study. J. Clin. Oncol. 1998; 16: 1444–1449, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Miles S. A., Dezube B. J., Lee J. Y., Krown S. E., Fletcher M. A., Saville M. W., Kaplan L., Groopman J., Scadden D. T., Cooley T., Von Roenn J., Friedman-Kien A. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16: 421–429, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tulpule A., Scadden D. T., Espina B. M., Cabriales S., Howard W., Shea K., Gill P. S. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 2000; 18: 716–723, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Little R. F., Wyvill K. M., Pluda J. M., Welles L., Marshall V., Figg W. D., Newcomb F. M., Tosato G., Feigal E., Steinberg S. M., Whitby D., Goedert J. J., Yarchoan R. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 2000; 18: 2593–2602, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cianfrocca M., Cooley T. P., Lee J. Y., Rudek M. A., Scadden D. T., Ratner L., Pluda J. M., Figg W. D., Krown S. E., Dezube B. J. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol. 2002; 20: 153–159, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Little R. F., Pluda J. M., Wyvill K., et al. Interleukin 12 (IL-12) Appears to be Active in AIDS-Associated Kaposi's Sarcoma (KS): Early Results of a Pilot Study. Proceedings of the 7th Conference on Retrovirus and Opportunistic Infections. 2002; 7, abstr 5
   Google Scholar
• Morfeldt L., Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand. J. Infect. Dis. 1994; 26: 749–752, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Mocroft A., Youle M., Gazzard B., Morcinek J., Halai R., Phillips A. N. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal free/chelsea and westminster Hospitals collaborative group. AIDS 1996; 10: 1101–1105, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Willers C. P., Reimann G., Mertins L., Brockmeyer N. H. Influence of foscarnet on HIV-associated Kaposi's sarcoma derived cell lines. Eur. J. Med. Res. 1999; 4: 514–516, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Scolaro M. J., Gunnill L. B., Pope L. E., Khalil M. H., Katz D. H., Berg J. E. The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV type 1-infected patients: a pilot clinical study. AIDS Res. Hum. Retrovir. 2001; 17: 35–43, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Senderowicz A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs 1999; 17: 313–320, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Melillo G., Sausville E. A., Cloud K., Lahusen T., Varesio L., Senderowicz A. M. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 1999; 59: 5433–5437, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chao S. H., Fujinaga K., Marion J. E., Taube R., Sausville E. A., Senderowicz A. M., Peterlin B. M., Price D. H. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 2000; 275: 28345–28348, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar